These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Improving the design of phase II trials of cytostatic anticancer agents. Stone A; Wheeler C; Barge A Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736 [TBL] [Abstract][Full Text] [Related]
4. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials. Calvert AH; Plummer R Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580 [TBL] [Abstract][Full Text] [Related]
5. Cancer clinical trials: development and implementation. Vail DM Vet Clin North Am Small Anim Pract; 2007 Nov; 37(6):1033-57; v. PubMed ID: 17950881 [TBL] [Abstract][Full Text] [Related]
6. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. El-Maraghi RH; Eisenhauer EA J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606 [TBL] [Abstract][Full Text] [Related]
7. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Suman VJ; Dueck A; Sargent DJ Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764 [No Abstract] [Full Text] [Related]
8. Evaluation of toxicity: statistical considerations. Herson J Cancer Treat Rep; 1980; 64(2-3):463-8. PubMed ID: 7407785 [TBL] [Abstract][Full Text] [Related]
9. Endpoints for agents that slow tumor growth. Yu RX; Holmgren E Contemp Clin Trials; 2007 Jan; 28(1):18-24. PubMed ID: 16829208 [TBL] [Abstract][Full Text] [Related]
10. Adaptive design may hasten clinical trials. Schmidt C J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993 [No Abstract] [Full Text] [Related]
11. Trend toward noninferiority trials may mean more difficult interpretation of trial results. Tuma RS J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926 [No Abstract] [Full Text] [Related]
12. Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ; J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802 [TBL] [Abstract][Full Text] [Related]
13. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846 [TBL] [Abstract][Full Text] [Related]
14. Multi-arm clinical trials of new agents: some design considerations. Freidlin B; Korn EL; Gray R; Martin A Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449 [TBL] [Abstract][Full Text] [Related]
15. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease. Pocard M; Soria JC; Aldaz-Carroll L; Bellet D J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954 [No Abstract] [Full Text] [Related]
16. Examining heterogeneity in phase II trial designs may improve success in phase III. Tuma RS J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788 [No Abstract] [Full Text] [Related]
17. Optimizing randomized phase II trials assessing tumor progression. Stone A; Wheeler C; Carroll K; Barge A Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129 [TBL] [Abstract][Full Text] [Related]
18. Improving the evaluation of new cancer treatments: challenges and opportunities. Rothenberg ML; Carbone DP; Johnson DH Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669 [TBL] [Abstract][Full Text] [Related]
19. Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Takimoto CH Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251 [TBL] [Abstract][Full Text] [Related]